JP2018535668A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535668A5
JP2018535668A5 JP2018519710A JP2018519710A JP2018535668A5 JP 2018535668 A5 JP2018535668 A5 JP 2018535668A5 JP 2018519710 A JP2018519710 A JP 2018519710A JP 2018519710 A JP2018519710 A JP 2018519710A JP 2018535668 A5 JP2018535668 A5 JP 2018535668A5
Authority
JP
Japan
Prior art keywords
seq
antigen recognition
recognition construct
tcr
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018519710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535668A (ja
JP7000315B2 (ja
Filing date
Publication date
Priority claimed from EP15190230.1A external-priority patent/EP3156067A1/en
Application filed filed Critical
Publication of JP2018535668A publication Critical patent/JP2018535668A/ja
Publication of JP2018535668A5 publication Critical patent/JP2018535668A5/ja
Application granted granted Critical
Publication of JP7000315B2 publication Critical patent/JP7000315B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018519710A 2015-10-16 2016-10-13 高結合活性hpv t細胞受容体 Expired - Fee Related JP7000315B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15190230.1 2015-10-16
EP15190230.1A EP3156067A1 (en) 2015-10-16 2015-10-16 High avidity hpv t-cell receptors
PCT/EP2016/074612 WO2017064198A1 (en) 2015-10-16 2016-10-13 High avidity hpv t-cell receptors

Publications (3)

Publication Number Publication Date
JP2018535668A JP2018535668A (ja) 2018-12-06
JP2018535668A5 true JP2018535668A5 (enExample) 2019-11-21
JP7000315B2 JP7000315B2 (ja) 2022-02-04

Family

ID=54359849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018519710A Expired - Fee Related JP7000315B2 (ja) 2015-10-16 2016-10-13 高結合活性hpv t細胞受容体

Country Status (7)

Country Link
US (1) US11401316B2 (enExample)
EP (2) EP3156067A1 (enExample)
JP (1) JP7000315B2 (enExample)
CN (1) CN108135998B (enExample)
AU (1) AU2016336817C1 (enExample)
CA (1) CA3001395A1 (enExample)
WO (1) WO2017064198A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018006789A (es) 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
DE102017114737A1 (de) 2017-06-30 2019-01-03 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
CN109053879B (zh) * 2018-08-22 2020-12-25 深圳市宝安区中心医院 一种治疗宫颈癌的scFv抗体及其应用
WO2020214957A1 (en) 2019-04-19 2020-10-22 Tcrcure Biopharma Corp. Anti-pd-1 antibodies and uses thereof
CN113072635B (zh) * 2020-01-06 2023-08-25 香雪生命科学技术(广东)有限公司 一种识别hpv抗原的t细胞受体及其编码序列
WO2021155518A1 (en) * 2020-02-05 2021-08-12 Tcrcure Biopharma Corp Anti-hpv t cell receptors and engineered cells
CN113321726B (zh) * 2020-02-28 2024-05-28 香雪生命科学技术(广东)有限公司 一种识别hpv的t细胞受体
EP4125949A4 (en) * 2020-03-23 2024-05-22 The Council of the Queensland Institute of Medical Research Compositions and methods for targeting hpv-infected cells
US20230227526A1 (en) * 2020-06-09 2023-07-20 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
WO2022060904A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
CN114539385A (zh) * 2020-11-26 2022-05-27 香雪生命科学技术(广东)有限公司 一种识别hpv抗原的tcr
CN114853878A (zh) * 2021-02-03 2022-08-05 香雪生命科学技术(广东)有限公司 一种针对hpv的高亲和力tcr
KR20230165771A (ko) 2021-03-03 2023-12-05 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법 및 dgk 억제제의 조합
WO2023014337A1 (en) * 2021-08-04 2023-02-09 GUERRERO PRESTON Rafael Viral and host biomarkers for early detection, therapeutic effectiveness, and relapse monitoring of cancer linked to severe acute respiratory syndrome coronavirus 2 and human papilloma virus
CN116262779A (zh) * 2021-12-14 2023-06-16 深圳先进技术研究院 一种单细胞筛选鉴定人乳头瘤病毒特异性tcr的方法
CN117402232A (zh) * 2022-05-10 2024-01-16 广州医科大学 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr
CN115286690B (zh) * 2022-05-10 2023-06-20 广州医科大学 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr
CN120152717A (zh) 2022-09-08 2025-06-13 朱诺治疗学股份有限公司 T细胞疗法和连续或间歇dgk抑制剂给药的组合
GB202311170D0 (en) * 2023-07-20 2023-09-06 Univ Oxford Innovation Ltd Antigen binding polypeptides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US20070218080A1 (en) 2006-03-14 2007-09-20 Mackay Memorial Hospital Peptide antigen of human papillomavirus type 16 and application thereof
EP2197910A2 (en) * 2007-09-25 2010-06-23 The United States of America, as represented by the Secretary, Department of Health and Human Services Modified t cell receptors and related materials and methods
BR112013006718B1 (pt) * 2010-09-20 2021-12-07 Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
US10946104B2 (en) 2012-01-13 2021-03-16 Apo-Tb.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
WO2014003552A1 (en) 2012-06-26 2014-01-03 Apo-T B.V. Binding molecules targeting pathogens
CN110511960B (zh) * 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
GB201322430D0 (en) 2013-12-18 2014-02-05 Immunocore Ltd T cell receptors
US10202640B2 (en) * 2014-05-07 2019-02-12 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing

Similar Documents

Publication Publication Date Title
JP2018535668A5 (enExample)
JP2016505635A5 (enExample)
RU2733754C2 (ru) Общие неоантигены
US20220170097A1 (en) Car t cell transcriptional atlas
PH12019501241A1 (en) Novel t cell receptors and immune therapy using the same
CA3045233A1 (en) Novel t cell receptors and immune therapy using the same
MX2023003463A (es) Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame.
PH12020550600A1 (en) Novel engineered t cell receptors and immune therapy using the same
JP2019511222A5 (enExample)
JP2020500523A5 (enExample)
WO2018172533A3 (en) T cell receptors and immune therapy using the same against prame positive cancers
JP2018509163A5 (enExample)
FI3250592T3 (fi) Transtyretiinin vastaisia vasta-aineita
PH12019500312A1 (en) T cell receptors and immune therapy using the same
CN105384825A (zh) 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN108299561A (zh) 一种pd-1纳米抗体及其克隆表达方法与应用
Soong et al. Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors
WO2021247534A2 (en) Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes
JP2016520053A5 (enExample)
Ligtenberg et al. Cripto-1 vaccination elicits protective immunity against metastatic melanoma
CN101643497A (zh) Lmp2a蛋白来源的hla-a2限制性表位多肽及其用途
CN107875376A (zh) 包含ny‑eso‑1的微泡、其制备方法及用途
CN113754756B (zh) 一种识别hla-a*02:01/e629-38的tcr及其应用
CN102250244A (zh) 人源抗人催乳素受体抗体及其应用
CN103524625B (zh) 一种新型诱导抗体产生的方法